問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

更新時間：2023-09-19

馬瑄吟
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

馬瑄吟

List

5Cases

2020-08-17 - 2023-10-31

Phase III

Completed
A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY

  • Condition/Disease

    Respiratory Tract Infection/RSV

  • Test Drug

    PF-06928316

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2021-01-01 - 2024-12-31

Phase III

Completed
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    RSVPreF3 vaccine, placebo

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2014-03-01 - 2016-03-31

Phase II

An Open-Label, Dose-Finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Paediatric Subjects aged 3 to 6 years and 2 to 35 months old

  • Condition/Disease

    Prevention of Enterovirus 71 infection

  • Test Drug

    EV71 vaccine

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Pediatrics

2021-02-01 - 2030-03-31

Phase III

A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen With Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared With a Standard 3-dose Regimen in 16- to 26-Year Old Women

  • Condition/Disease

    Human Papillomavirus(HPV) Infections

  • Test Drug

    Gardasil 9

Participate Sites
3Sites

Not yet recruiting3Sites

2014-09-01 - 2018-09-04

Phase III

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to NonAdjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.

  • Condition/Disease

    Vaccines to prevent influenza

  • Test Drug

    aQIV

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Pediatrics

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB